Xenpozyme Listed on LSDP for Niemann-Pick ASMD (Type A/B and Type B)
- ANPDF
- Oct 2
- 2 min read
On 1 October 2025, Sanofi announced that Xenpozyme® (olipudase alfa) has been listed on the Life Saving Drugs Program (LSDP) for patients with Acid Sphingomyelinase Deficiency (ASMD), also known as Niemann-Pick Disease Type A/B and Type B.
This is a significant milestone for the ASMD community in Australia, providing access to the first disease-specific therapy for those living with Niemann-Pick A/B and B. We send our congratulations to the families, advocates, and clinical teams who have worked tirelessly to achieve this outcome.
It is important to clarify that this listing does not include Niemann-Pick Disease Type C (NPC). At the Australian NPC Disease Foundation, we continue to advocate for access to effective treatments for NPC, including Arimoclomol and Miglustat, and to ensure our community’s needs remain visible in national policy discussions.
If you have any questions about what this means for NPC, please reach out to us at info@npcd.org.au.
ANPDF will continue to share updates as more information becomes available.
References & Further Information
Australian Government, Department of Health and Aged Care: Life Saving Drugs Program – ASMD resources
Sanofi Xenpozyme (olipudase alfa) information: XENPOZYME® (olipudase alfa-rpcp) for ASMD treatment (non-CNS manifestations)
Sanofi Australia: www.sanofi.com.au
Rare Voices Australia: Updates on rare disease policy and treatment access
What is the LSDP?
The Life Saving Drugs Program (LSDP) is an Australian Government program that provides free access to high-cost, life-saving medicines for people with very rare and life-threatening conditions.
Because the number of patients is so small, these medicines are often not subsidised on the PBS (Pharmaceutical Benefits Scheme) as they don’t meet the usual cost-effectiveness criteria. Instead, the LSDP exists to make sure patients can still access them if:
The disease is life-threatening, severely disabling, or both
The medicine has been proven safe and effective
There are no other suitable treatment options
The cost is too high for individuals to afford
Each condition and medicine is individually assessed, and if accepted, the government covers the full cost so patients don’t pay.
For ASMD (Niemann-Pick A/B and B), Xenpozyme® has just been added to the LSDP.
👉 For official details, the Department of Health and Aged Care has a page here: Life Saving Drugs Program – ASMD resources.
Comments